| Total: $709.15M | ||||
| Company (Symbol)# (M) | Type Of Financing | Number Of Shares, Units Or Warrants | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| Aastrom Biosciences Inc. (ASTM) | Registered direct offering | N/A | $13.5 | Aastrom entered agreements to raise $13.5M, selling 11.8M units at $1.14 each; each unit will consist of one share and one five-year warrant to purchase an additional half-share for $1.5875; BMO Capital Markets Corp. served as the placement agent (10/16) |
| Advaxis Inc. (OTC BB:ADXS) | Private placement of common stock and warrants | N/A | $9.4 | Advaxis raised $9.4M in a private placement; Carter Securities LLC acted as placement agent (10/18) |
| Anadis Ltd. (Australia; PK:ANDIF) | Private placement | N/A | $0.6 | Anadis raised $600,000 from U.S. and Australian investors (10/4) |
| Applied NeuroSolutions Inc. (OTC BB: APNS) | Private placement of common stock and warrants | 20.7S and 6.2W | $2.9 | Applied NeuroSolutions raised $2.9M placing 20.7M shares at 14 cents per share to SF Capital Partners Ltd.; it also issued 6.2M five-year warrants to purchase more shares at 19 cents each (10/2) |
| BioTime Inc. (OTC BB:BTIM) | Credit agreement | 0.2S | $1 | BioTime received $1M in credit after issuing 200,000 shares (10/18) |
| CombintoRx Inc. (CRXX) | Registered direct offering | 5.6S | $35 | CombinatoRx raised $35M issuing 5.6M shares at $6.25 each (10/11) |
| Cytokinetics Inc. (CYTK) | Commited equity financing facility | W for 0.23S | Cytokinetics secured the option to access up to $75M over the next three years through a facility with Kingsbridge Capital Ltd.; it issued Kingsbridge three-year warrants to purchase up to 230,000 shares of common stock at $7.99 per share (10/16) | |
| Dendreon Corp. (DNDN) | Private placement of common stock | N/A | $130 | Dendreon will sell up to $130M of its common stock to Azimuth Opportunity Ltd. over 18 months (10/12) |
| DUSA Pharmaceuticals Inc. (DUSA) | Private placement of common stock | 4.6S | $11 | DUSA raised $11M placing about 4.6M shares at $2.40 each; DUSA also issued warrants to buy an additional 1.1M shares at $2.85 each; Rodman & Renshaw LLC served as the placement agent, in which Deerfield Management and Greenway Capital invested (10/30) |
| Duska Therapeutics Inc. (OTC BB: DSKA) | Private placement of common stock and warrants | 14.3S and 14.3W | $5.75 | Duska raised $5.75M in a financing from three institutional investors (10/2) |
| Genelabs Technologies Inc. (GNLB) | Private placement of common stock and warrants | 12.9S and W for 2.6S | $23.7 | Genelabs raised $23.7M, selling units consisting of one share and one warrant to buy 0.2 share of stock priced at $1.84 per unit, with a $2.08 exercise price on the warrants; Deutsche Bank Securities Inc. acted as placement agent in the transaction (10/2) |
| Hana Biosciences Inc. (HNAB) | Loan agreement | N/A | $7.5 | Hana signed a loan agreement with Deerfield Management that will provide access to $7.5M up front and up to $30M in total over three years (10/31) |
| Living Cell Technologies Ltd. (Australia; PK:LVCLF) | Private placement | 22.4S | A$2.4($2.1) | Living Cell is raising $2.1M in a placement with NaviGroup Management Ltd. (10/4) |
| Living Cell Technologies Ltd. (Australia; PK:LVCLF) | Private placement of ordinary shares | 17.7S | A$6.4 ($5.8) | Living Cell raised $5.8M through the placement of 17.7M shares at A36 cents per share; this is in addition to a private placement that occurred earlier in October (10/30) |
| MacroChem Corp. (OTC BB: MACM) | Private placement of common stock and warrants | 5.9S and W for 1.8S | $3.5 | MacroChem raised $3.5M, issuing 5.9M shares and five-year warrants to buy 1.8M shares exercisable at 60 cents per share; Griffin Securities Inc. acted as placement agent (10/10) |
| MannKind Corp. (MNKD) | Registered direct offering | 15.9S | $250 | MannKind raised $250M offering 15.9M shares to Alfred Mann, the company's CEO and chairman, and offering the remaining 11.1M to investors, including accounts managed by Legg Mason Capital Management Inc. (10/2) |
| Medicure Inc. (Canada; TSX: MPH) | Private placement of common stock and warrants | 13.91S and W for 4.17S | $16 | Medicure raised $16M selling 13.91M shares at $1.15 each, together with warrants to buy 4.17M additional shares; Leerink Swann, A.G. Edwards & Sons Inc., Merriman Curhan Ford & Co., RBC Capital Markets Inc. and Noble Financial Group served as financial advisors (10/2) |
| OncoMethylome Sciences SA (Belgium; BR:ONCOB) | Private placement of common stock | 1.06S | €10.6($15) | OncoMethylome raised $15M in a placement of 1.06M shares priced at €10 per share; Piper Jaffray Ltd., Kempen & Co. and ING Belgium served as placement agents (10/16) |
| Optimer Pharmaceuticals Inc. (OPTR) | Private placement of common stock | 4.6S | $35.9 | Optimer is raising $35.9M through the placement of 4.6M shares at $7.80 each; Piper Jaffray & Co. acted as the exclusive placement agent (10/24) |
| Osiris Therapeutics Inc. (OSIR) | Financing agreement | ND | $30 | Osiris entered into a $30M agreement with Friedli Corporate Finance Inc. |
| Pharmasset Inc. (VRUS) | Loan agreement | W for 0.15S | $10 | Pharmasset is receiving $10M from Horizon Technology Finance LLC, and can access another $10M by March and a third loan of $10M by November 2008; Horizon also received a warrant to purchase up to 149,377 shares at $12.05 per share (10/5) |
| Pharmaxis (Australia; PXSL) | Private placement of common stock | 12.8S | A$50($45.2) | Pharmaxis raised $45.2M through a placement of 12.8M new fully paid ordinary shares at A$3.90 per share (10/11) |
| Protox Therapeutics Inc. (Canada; CDNX:PRX) | Exercise of warrants | N/A | $5.2 | Protox received about $5.2M of a potential $7.7M from the exercise of warrants issued in November 2005 (10/26) |
| SemBioSys Genetics Inc. (Canada; TSX:SBS) | Private placement of units | 2.5U | $6.5 | SemBioSys is raising $6.5M issuing 2.5M units, with each unit consisting of one common share and one half of a common share purchase warrant, priced at $2.60 each, on a bought-deal private placement basis, to underwriters led by Acumen Capital Finance Partners Ltd., and including PI Financial Corp.; the underwriters also have an overallotment option for an additional 1.18M units (10/19) |
| Sequenom Inc. (SQNM) | Private placement of common stock | 3.4S | $30 | Sequenom is raising $30M through the sale of about 3.4M shares at $9 each; Lehman Brothers Inc. and UBS Investment Bank served as joint lead placement agents, while Oppenheimer & Co., Leerink Swann LLC and Rodman & Renshaw LLC acted as co-placement agents (10/26) |
| Transdel Pharmaceuticals Inc. (OTC BB: TDLP) | Private placement of common stock and warrants | ND | $4 | Transdel raised $4M through the sale (10/1) |
| XTL Biopharma-ceuticals Ltd. (XTLB) | Private placement of ordinary shares | N/A | $9.6 | XTL raised $9.6M in gross proceeds of ordinary shares, represented by American depositary receipts; lead investors are Perceptive Life Sciences Fund, Quogue Capital LLC, SCO Capital Partners and Versant Capital (10/25) |
|
Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced. # Unless otherwise indicated, shares are traded on the Nasdaq exchange@ Refers to the date of the press release. ** Denotes the date the item ran in BioWorld International.Currency conversions are based on exchange rates at the time of the deal. N/A = Not applicable; ND = Not disclosed.BR = Brussels Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.